More Articles

Successful phase III trial of biosimilar r-FSH Biosimilars/News | Posted 18/06/2012

Finox Biotech announced on 6 June 2012 that the company’s pivotal phase III study with Afolia, a biosimilar recombinant follicle stimulating hormone (r-FSH), in patients undergoing assisted reprodu...

Drug shortages are persisting Pharma News | Posted 08/06/2012

The media are reporting continuing problems on drug shortages, and indeed a worsening situation around the world. Cancer drugs seem to be the most affected.

EMA opens up access to reports on suspected drug side effects Policies & Legislation | Posted 08/06/2012

In its commitment to transparency, EMA, on 31 May 2012, opened up access to reports on suspected drug side effects. The database contains reports on around 650 medications and active ingredients, i...

Attitudes and beliefs are powerful influences on generics use Generics/Research | Posted 08/06/2012

While generic drugs have the potential to provide significant savings in healthcare costs, and numerous financial incentives are in place, the generics substitution rate in Switzerland was, until r...

Merck KGaA and Dr Reddy’s to collaborate on biosimilar mAbs Biosimilars/News | Posted 08/06/2012

Pharma major Merck KGaA announced on 6 June 2012 its first steps into the biosimilars market, with an agreement with India-based generics manufacturer Dr Reddy’s Laboratories (Dr Reddy’s) to co-dev...

EMA revised guideline on quality of biosimilar medicines open for comments Guidelines | Posted 08/06/2012

EMA announced on 31 May 2012 that it had released a revised guideline for public consultation describing how pharmaceutical companies should address the quality aspects of biosimilar medicines.

Which antiplatelet agent? The debate intensifies Generics/General | Posted 08/06/2012

Plavix (clopidogrel) has been a blockbuster drug. The lower cost of generic clopidogrel, available for the first time since 17 May 2012 [1], is intensifying debate among cardiologists over how to m...

Teva won’t sell generic atorvastatin Generics/News | Posted 08/06/2012

Teva has decided not to market its own generic version of Lipitor (atorvastatin), Pfizer’s blockbuster cholesterol-lowering drug that recently came off patent. The decision comes despite the fact t...